• Tidak ada hasil yang ditemukan

MANAGING COMORBIDITIES

Dalam dokumen GINA 2016 main report tracked (Halaman 61-64)

Treating asthma to control symptoms

MANAGING COMORBIDITIES

Several comorbidities are commonly present in patients with asthma, particularly those with difficult-to-treat or severe asthma. Active management of comorbidities is recommended because they may contribute to symptom burden, impair quality of life, and lead to medication interactions. Some comorbidities also contribute to poor asthma control.251 Obesity

Clinical features

Asthma is more difficult to control in obese patients.252-255 This may be due to a different type of airway inflammation, contributory comorbidities such as obstructive sleep apnea and gastroesophageal reflux disease (GERD), mechanical factors, or other as yet undefined factors. In addition, lack of fitness and reduction in lung volume due to abdominal fat may contribute to dyspnea.

Diagnosis

Document body mass index (BMI) for all patients with asthma. Because of other potential contributors to dyspnea and wheeze in obese patients, it is important to confirm the diagnosis of asthma with objective measurement of variable airflow limitation (Box 1-2, p.17). Asthma is more common in obese than non-obese patients,45 but both over- and under-diagnosis of asthma occur in obesity.41,46

Management

As for other patients with asthma, ICS are the mainstay of treatment in obese patients (Evidence B), although their response may be reduced.255 Weight reduction should be included in the treatment plan for obese patients with asthma (Evidence B). Increased exercise alone appears to be insufficient (Evidence B).256 Weight loss improves asthma control, lung function, health status and reduces medication needs in obese patients,257,258 but the quality of some studies is poor. The most striking results have been observed after bariatric surgery,259,260 but even 5–10% weight loss can lead to improved asthma control and quality of life.256

Gastroesophageal reflux disease (GERD) Clinical features

GERD can cause symptoms such as heartburn, and epigastric or chest pain, and is also a common cause of dry cough.

Symptoms and/or diagnosis of GERD are more common in people with asthma than in the general population,251 but this may be in part due to cough being attributed to asthma; in addition, some asthma medications such as beta2 -agonists and theophylline cause relaxation of the lower esophageal sphincter. Asymptomatic gastroesophageal reflux is not a likely cause of poorly controlled asthma.251

Diagnosis

In patients with confirmed asthma, GERD should be considered as a possible cause of a dry cough; however, there is no value in screening patients with uncontrolled asthma for GERD (Evidence A). For patients with asthma and symptoms suggestive of reflux, an empirical trial of anti-reflux medication, such as a proton pump inhibitor or motility agent, may be considered, as in the general population. If the symptoms do not resolve, specific investigations such as 24-hour pH monitoring or endoscopy may be considered.

Management

A review of proton pump inhibitors in patients with confirmed asthma, most of whom had a diagnosis of GERD, showed a significant but small benefit for morning PEF, but no significant benefit for other asthma outcomes.261 In a study of adult patients with symptomatic asthma but without symptoms of GERD, treatment with high-dose proton pump inhibitors did not reduce asthma symptoms or exacerbations.262 In general, benefits of proton pump inhibitors in asthma appear to be limited to patients with both symptomatic reflux and night-time respiratory symptoms.263 Other treatment options include motility agents, lifestyle changes and fundoplication. In summary, symptomatic reflux should be treated, but patients with poorly controlled asthma should not be treated with anti-reflux therapy unless they also have symptomatic reflux (Evidence A). Few data are available for children with asthma symptoms and symptoms of GERD.264,265

Anxiety and depression Clinical features

Psychiatric disorders, particularly depressive and anxiety disorders, are more prevalent among people with asthma.266 Psychiatric comorbidity is also associated with worse asthma symptom control and medication adherence, and worse asthma-related quality of life.267 Anxious and depressive symptoms have been associated with increased asthma-related exacerbations and emergency visits.268 Panic attacks may be mistaken for asthma.

Diagnosis

Although several tools are available for screening for anxious and depressive symptomatology in primary care, the majority have not been validated in asthma populations. Difficulties in distinguishing anxiety or depression from asthma symptoms may therefore lead to misdiagnosis. It is important to be alert to possible depression and/or anxiety in people with asthma, particularly when there is a previous history of these conditions. Where appropriate, patients should be referred to psychiatrists or evaluated with a disease-specific psychiatric diagnostic tool to identify potential cases of depression and/or anxiety.

Management

There have been few good quality pharmacological and non-pharmacological treatment trials for anxiety or depression in patients with asthma, and results are inconsistent. A Cochrane review of 15 randomized controlled trials of

psychological interventions for adults with asthma included cognitive behavior therapy, psychoeducation, relaxation, and biofeedback.269 Results for anxiety were conflicting, and none of the studies found significant treatment differences for depression. Drug treatments and cognitive behavior therapy270 have been described as having some potential in

patients with asthma; however, current evidence is limited, with a small number of studies and methodological shortcomings.

Food allergy and anaphylaxis Clinical features

Rarely, food allergy is a trigger for asthma symptoms (<2% of people with asthma). In patients with confirmed food-induced allergic reactions (anaphylaxis), co-existing asthma is a strong risk factor for more severe and even fatal reactions. Food-induced anaphylaxis often presents as life-threatening asthma.86 An analysis of 63 anaphylaxis-related deaths in the United States noted that almost all had a past history of asthma; peanuts and tree nuts were the foods most commonly responsible.271 A UK study of 48 anaphylaxis-related deaths found that most were regularly treated for asthma, and that in most of these, asthma was poorly controlled.272

Diagnosis

In patients with confirmed food allergy, it is important to assess for asthma. Children with food allergy have a four-fold increased likelihood of having asthma compared with children without food allergy.273 Refer patients with suspected food allergy or intolerance for specialist allergy assessment. This may include appropriate allergy testing such as skin prick testing and/or blood testing for specific IgE. On occasion, carefully supervised food challenges may be needed.

Management

Patients who have a confirmed food allergy that puts them at risk for anaphylaxis must be trained and have an epinephrine auto-injector available at all times. They, and their family, must be educated in appropriate food avoidance strategies, and in the medical notes, they should be flagged as being at high risk. It is especially important to ensure that their asthma is well controlled, they have a written action plan, understand the difference between asthma and

anaphylaxis, and are reviewed on a regular basis.

Rhinitis, sinusitis and nasal polyps Clinical features

Evidence clearly supports a link between diseases of the upper and lower airways.274 Most patients with asthma, either allergic or non-allergic, have concurrent rhinitis, and 10–40% of patients with allergic rhinitis have asthma.275 Depending on sensitization and exposure, allergic rhinitis may be seasonal (e.g. ragweed or grass pollen), perennial (e.g. mite allergens), or intermittent (e.g. furred pets).274

Rhinitis is defined as irritation and inflammation of the mucous membranes of the nose. Allergic rhinitis may be accompanied by ocular symptoms (conjunctivitis). Rhinosinusitis is defined as inflammation of the nose and paranasal sinuses characterized by more than two symptoms including nasal blockage/obstruction and/or nasal discharge (anterior/posterior nasal drip).276 Other symptoms may include facial pain/pressure and/or a reduction or loss of smell.

Sinusitis rarely occurs in the absence of rhinitis.

Rhinosinusitis is defined as acute when symptoms last <12 weeks with complete resolution, and chronic when symptoms occur on most days for at least 12 weeks without complete resolution. Chronic rhinosinusitis is an inflammatory condition of the paranasal sinuses that encompasses two clinically distinct entities: chronic rhinosinusitis without nasal polyposis and chronic rhinosinusitis with nasal polyposis.277 The heterogeneity of chronic rhinosinusitis may explain the wide variation in prevalence rates in the general population ranging from 1–10% without polyps and 4%

with polyps. Chronic rhinosinusitis is associated with more severe asthma, especially in patients with nasal polyps.278 Diagnosis

Rhinitis can be classified as either allergic or non-allergic depending on whether allergic sensitization is demonstrated.

Variation in symptoms by season or with environmental exposure (e.g. furred pets) suggests allergic rhinitis.

Examination of the upper airway should be arranged for patients with severe asthma.

Management

Evidence-based guidelines (Allergic Rhinitis in Asthma, ARIA)279 recommend intranasal corticosteroids for treatment of allergic rhinitis. In population-based studies, treatment of rhinitis with intranasal corticosteroids is associated with less need for asthma-related hospitalization and emergency department visits.280 However, few placebo-controlled studies have systematically evaluated the effect of proper treatment and management of chronic rhinosinusitis on asthma control.

Dalam dokumen GINA 2016 main report tracked (Halaman 61-64)